PMC:7536919 / 97-1212 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":66,"end":70},"obj":"Body_part"},{"id":"T2","span":{"begin":188,"end":197},"obj":"Body_part"},{"id":"T3","span":{"begin":193,"end":197},"obj":"Body_part"},{"id":"T4","span":{"begin":927,"end":935},"obj":"Body_part"},{"id":"T5","span":{"begin":930,"end":935},"obj":"Body_part"},{"id":"T6","span":{"begin":1013,"end":1023},"obj":"Body_part"},{"id":"T7","span":{"begin":1024,"end":1028},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":135,"end":143},"obj":"Disease"},{"id":"T3","span":{"begin":247,"end":255},"obj":"Disease"},{"id":"T4","span":{"begin":336,"end":343},"obj":"Disease"},{"id":"T5","span":{"begin":438,"end":445},"obj":"Disease"},{"id":"T6","span":{"begin":1097,"end":1105},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":45,"end":48},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T2","span":{"begin":50,"end":53},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T3","span":{"begin":64,"end":70},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T4","span":{"begin":188,"end":197},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T5","span":{"begin":207,"end":208},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":231,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T7","span":{"begin":318,"end":319},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":421,"end":422},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":614,"end":615},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":699,"end":700},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T11","span":{"begin":761,"end":762},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T12","span":{"begin":927,"end":935},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T13","span":{"begin":971,"end":972},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":1024,"end":1028},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":294,"end":299},"obj":"Chemical"},{"id":"T2","span":{"begin":1040,"end":1042},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74561"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":879,"end":902},"obj":"http://purl.obolibrary.org/obo/GO_0045087"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":144},"obj":"Sentence"},{"id":"T6","span":{"begin":145,"end":265},"obj":"Sentence"},{"id":"T7","span":{"begin":266,"end":384},"obj":"Sentence"},{"id":"T8","span":{"begin":385,"end":525},"obj":"Sentence"},{"id":"T9","span":{"begin":526,"end":797},"obj":"Sentence"},{"id":"T10","span":{"begin":798,"end":1115},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"18","span":{"begin":45,"end":48},"obj":"Gene"},{"id":"19","span":{"begin":50,"end":53},"obj":"Gene"},{"id":"20","span":{"begin":361,"end":383},"obj":"Gene"},{"id":"21","span":{"begin":1040,"end":1044},"obj":"Gene"},{"id":"22","span":{"begin":121,"end":129},"obj":"Species"},{"id":"23","span":{"begin":256,"end":264},"obj":"Species"},{"id":"24","span":{"begin":516,"end":524},"obj":"Species"},{"id":"25","span":{"begin":678,"end":686},"obj":"Species"},{"id":"26","span":{"begin":1106,"end":1114},"obj":"Species"},{"id":"27","span":{"begin":106,"end":120},"obj":"Disease"},{"id":"28","span":{"begin":135,"end":143},"obj":"Disease"},{"id":"29","span":{"begin":247,"end":255},"obj":"Disease"},{"id":"30","span":{"begin":336,"end":343},"obj":"Disease"},{"id":"31","span":{"begin":438,"end":445},"obj":"Disease"},{"id":"32","span":{"begin":768,"end":786},"obj":"Disease"},{"id":"33","span":{"begin":1097,"end":1105},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Gene:920"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Gene:925"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:4582"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:4582"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Tax:9606"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:9606"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:9606"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:9606"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D016638"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:C000657245"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:C000657245"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D001523"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It is widely reported in the literature that CD4, CD8 and total T cell count are significantly reduced in critically ill patients with COVID‐19. Few weeks ago, we suggested natural killer (NK) cell count as a marker of severity in 34 hospitalized COVID‐19 patients. On this topic, our research group firstly described a novel potential COVID19 severity marker, Krebs von den Lungen‐6. This study aimed to investigate how a combination of COVID19 severity markers could be helpful in the clinical management of these patients. The combination of these validated, reproducible and non‐expensive bioindicators showed a good accuracy in discriminating between severe and non‐severe patients, suggesting a promising value of this approach in the early prediction of a more aggressive disease phenotype. Despite its monocentric design, our study confirms the reliable dysregulation of innate immune responses, particularly involving NK cells, and suggests that surveillance of a peripheral biomarkers’ panel, including lymphocyte cell counts and KL‐6, may be useful in the clinical management of severe COVID‐19 patients."}